Top Markets
#1 ADO Protocol ADO Protocol +329.44%
#2 GoPlus Security GoPlus Security +53.12%
#3 Verus Coin Verus Coin +43.46%
#4 The Black Bull The Black Bull +42.41%
#5 Nockchain Nockchain +40.58%
#6 Starpower Starpower +35.32%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +33.57%
#8 Tutorial Tutorial +27.99%
#9 Fake World Assets Fake World Assets +25.51%
#10 GAIB AID GAIB AID +24.67%
Coin of the day
ADO Protocol ADO Protocol
설정
언어
한국어
통화
USD
테마
NuCana plc NuCana plc

NuCana plc

NCNA
주식 순위 #32729
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
주가
$1.56
시가총액
$9.44M
변동 (1일)
-2.20%
변동 (1년)
-58.31%
국가
GB
거래 NuCana plc (NCNA)

카테고리

Healthcare
NuCana plc (NCNA)의 EPS
2026 기준 EPS TTM: 0
NuCana plc의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
NuCana plc의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -
BE